HRP20150797T1 - Supstituirani derivati ksantina - Google Patents
Supstituirani derivati ksantina Download PDFInfo
- Publication number
- HRP20150797T1 HRP20150797T1 HRP20150797TT HRP20150797T HRP20150797T1 HR P20150797 T1 HRP20150797 T1 HR P20150797T1 HR P20150797T T HRP20150797T T HR P20150797TT HR P20150797 T HRP20150797 T HR P20150797T HR P20150797 T1 HRP20150797 T1 HR P20150797T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound according
- compound
- enrichment factor
- disease
- kidney disease
- Prior art date
Links
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 title 1
- 229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 12
- 229910052805 deuterium Inorganic materials 0.000 claims 4
- 230000000155 isotopic effect Effects 0.000 claims 4
- 125000004431 deuterium atom Chemical group 0.000 claims 3
- 208000020832 chronic kidney disease Diseases 0.000 claims 2
- 200000000007 Arterial disease Diseases 0.000 claims 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 206010055171 Hypertensive nephropathy Diseases 0.000 claims 1
- 206010022562 Intermittent claudication Diseases 0.000 claims 1
- 206010029164 Nephrotic syndrome Diseases 0.000 claims 1
- 208000026723 Urinary tract disease Diseases 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000005206 focal segmental glomerulosclerosis Diseases 0.000 claims 1
- 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 claims 1
- 208000021156 intermittent vascular claudication Diseases 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 208000030761 polycystic kidney disease Diseases 0.000 claims 1
- 238000010992 reflux Methods 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/10—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 3 and 7, e.g. theobromine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Child & Adolescent Psychology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- AIDS & HIV (AREA)
- Vascular Medicine (AREA)
- Toxicology (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
Claims (10)
1. Spoj sa slijedećom formulom:
[image]
ili njegova farmaceutski prihvatljiva sol, naznačen time da je faktor izotopskog obogaćenja za svaki naznačeni atom deuterija najmanje 5000.
2. Spoj prema zahtjevu 1, naznačen time da je svaki atom, koji nije označen kao deuterij, prisutan u svom prirodnom izotopskom suvišku.
3. Spoj prema zahtjevu 2, naznačen time da je faktor izotopskog obogaćenja za svaki naznačeni atom deuterija najmanje 6000.
4. Spoj prema zahtjevu 2, naznačen time da je faktor izotopskog obogaćenja za svaki naznačeni atom deuterija najmanje 6600.
5. Spoj prema bilo kojem od zahtjeva 1 do 4, naznačen time da spoj sadrži manje od 10% drugog stereoizomera.
6. Spoj prema zahtjevu 5, naznačen time da spoj sadrži manje od 5% drugog stereoizomera.
7. Farmaceutski pripravak naznačen time da sadrži spoj prema bilo kojem od zahtjeva 1 do 6 i farmaceutski prihvatljiv nosač.
8. Spoj prema bilo kojem od zahtjeva 1 do 6, naznačen time da je za uporabu za liječenje bolesti ili stanja odabranog od dijabetičke nefropatije, hipertenzivne nefropatije ili povremenog šepanja zbog kronične okluzivne arterijske bolesti udova
9. Spoj prema bilo kojem od zahtjeva 1 do 6, naznačen time da je za uporabu za liječenje kronične bolesti bubrega.
10. Spoj za uporabu prema zahtjevu 9, naznačen time da kronična bolest bubrega je glomerulonefritis, fokalna segmentna glomeruloskleroza, nefrotski sindrom, refluks uropatija ili policistična bolest bubrega.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23934209P | 2009-09-02 | 2009-09-02 | |
US12/873,991 US20110053961A1 (en) | 2009-02-27 | 2010-09-01 | Substituted xanthine derivatives |
EP20100814504 EP2473053B1 (en) | 2009-09-02 | 2010-09-02 | Substituted xanthine derivatives |
PCT/US2010/047708 WO2011028922A1 (en) | 2009-09-02 | 2010-09-02 | Substituted xanthine derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20150797T1 true HRP20150797T1 (hr) | 2015-09-11 |
Family
ID=43625765
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20150797TT HRP20150797T1 (hr) | 2009-09-02 | 2015-07-20 | Supstituirani derivati ksantina |
Country Status (22)
Country | Link |
---|---|
US (1) | US20110053961A1 (hr) |
EP (2) | EP2963040A1 (hr) |
JP (1) | JP5292516B2 (hr) |
KR (1) | KR101591137B1 (hr) |
CN (2) | CN102480968B (hr) |
AU (1) | AU2010289465B2 (hr) |
BR (1) | BR112012008108B1 (hr) |
CA (1) | CA2771123C (hr) |
DK (1) | DK2473053T3 (hr) |
EA (1) | EA023809B1 (hr) |
ES (1) | ES2542401T3 (hr) |
HK (1) | HK1170377A1 (hr) |
HR (1) | HRP20150797T1 (hr) |
HU (1) | HUE026800T2 (hr) |
IN (1) | IN2012DN01641A (hr) |
ME (1) | ME02177B (hr) |
MX (1) | MX2012002705A (hr) |
PL (1) | PL2473053T3 (hr) |
PT (1) | PT2473053E (hr) |
SI (1) | SI2473053T1 (hr) |
WO (1) | WO2011028922A1 (hr) |
ZA (1) | ZA201201295B (hr) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2716788C (en) | 2008-02-29 | 2016-08-16 | Concert Pharmaceuticals, Inc. | Deuterium-substituted xanthine derivatives |
WO2010075086A2 (en) * | 2008-12-15 | 2010-07-01 | Auspex Pharmaceuticals, Inc. | Pyrrolidinone inhibitors of pde-4 |
US8263601B2 (en) * | 2009-02-27 | 2012-09-11 | Concert Pharmaceuticals, Inc. | Deuterium substituted xanthine derivatives |
WO2011028820A1 (en) | 2009-09-02 | 2011-03-10 | Concert Pharmaceuticals, Inc. | Substituted derivatives of bicyclic [4.3.0] heteroaryl compounds |
MX2012002704A (es) * | 2009-09-02 | 2012-03-21 | Concert Pharmaceuticals Inc | Derivados de xantina sustituidos. |
US9085788B2 (en) | 2010-09-01 | 2015-07-21 | Concert Pharmaceuticals, Inc. | Process for preparing an enantiomerically enriched, deuterated secondary alcohol from a corresponding ketone without reducing deuterium incorporation |
US20130324564A1 (en) * | 2010-09-01 | 2013-12-05 | Concert Pharmaceuticals, Inc. | Polymorphs of (s)-1-(4,4,6,6,6-pentadeutero-5-hydroxyhexyl)-3-7-dimethyl-1h-purine-2,6(3h,7h)-dione |
WO2012031073A1 (en) | 2010-09-01 | 2012-03-08 | Concert Pharmaceuticals, Inc. | Process for preparing an enantiomerically enriched, deuterated secondary alcohol from a corresponding ketone without reducing deuterium incorporation |
MX2014012384A (es) | 2012-04-13 | 2014-11-26 | Concert Pharmaceuticals Inc | Derivados sustituidos de xantina. |
WO2013159006A1 (en) * | 2012-04-20 | 2013-10-24 | Concert Pharmaceuticals, Inc. | Polymorphs of (s)-1-(4,4,6,6,6-pentadeutero-5-hydroxyhexyl)-3,7-dimethyl-1h-purine-2,6(3h,7h)-dione |
CN106456647A (zh) * | 2014-04-18 | 2017-02-22 | 康塞特医药品有限公司 | 治疗高血糖症的方法 |
WO2015175008A1 (en) * | 2014-05-14 | 2015-11-19 | Concert Pharmaceuticals, Inc. | Methods of treating chronic kidney disease characterized by macroalbuminuria |
WO2015184248A1 (en) * | 2014-05-30 | 2015-12-03 | Concert Pharmaceuticals, Inc. | Methods of treating fibrotic diseases |
AU2015330490B2 (en) * | 2014-10-09 | 2018-08-09 | Guangdong Raynovent Biotech Co., Ltd. | Hydroxyl purine compounds and applications thereof |
CN105566324B (zh) * | 2014-10-09 | 2020-04-03 | 广东众生睿创生物科技有限公司 | 羟基嘌呤类化合物及其应用 |
US10278973B2 (en) * | 2015-05-20 | 2019-05-07 | Guangdong Raynovent Biotech Co., Ltd. | Hydroxyl purine compounds and use thereof |
CN108137592B (zh) * | 2015-11-03 | 2021-03-05 | 纽弗姆制药有限公司 | 用于治疗血癌的氘代化合物以及其组合物和方法 |
WO2017087207A1 (en) * | 2015-11-16 | 2017-05-26 | NeuForm Pharmaceuticals, Inc. | Deuterated compounds for treating hematologic malignant, inflammatory and autoimmune diseases |
US20220380370A1 (en) * | 2019-09-25 | 2022-12-01 | Goldfinch Bio, Inc. | Xanthine cb1 inhibitors |
CN111440041B (zh) * | 2020-05-19 | 2021-03-05 | 北京理工大学 | 一种甲苯-d8的合成方法 |
CN114380829A (zh) * | 2021-12-28 | 2022-04-22 | 赤峰万泽药业股份有限公司 | 一种己酮可可碱及其合成方法和应用 |
Family Cites Families (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE793059A (fr) | 1972-02-28 | 1973-04-16 | Ritzerfeld Gerhard | Dispositif d'encrage pour presses rotatives a |
JPS5632477B2 (hr) | 1973-03-07 | 1981-07-28 | ||
DE2330742C2 (de) | 1973-06-16 | 1982-07-29 | Hoechst Ag, 6000 Frankfurt | 1-(Oxoalkyl)-3-methyl-7-alkylxanthine, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel |
JPS5610188B2 (hr) | 1973-09-14 | 1981-03-06 | ||
JPS5756481B2 (hr) | 1974-06-13 | 1982-11-30 | ||
CA1037234A (en) | 1976-06-01 | 1978-08-29 | Aluma Building Systems Incorporated | Wall forming structure for poured concrete walls |
FR2376188A1 (fr) | 1976-12-28 | 1978-07-28 | Elf Union | Procede de preparation de compositions de bitumes polymeres |
JPS54120627A (en) | 1978-03-13 | 1979-09-19 | Nittetsu Kakoki Kk | Regenaration of asphalt concrete |
JPS5576876A (en) | 1978-12-05 | 1980-06-10 | Grelan Pharmaceut Co Ltd | Preparation of 1-(oxoalkyl)-3,7-dimethylxanthine derivatne |
JPS5581055A (en) | 1978-12-12 | 1980-06-18 | Kubota Ltd | Drawing device of pipe |
JPS55122779A (en) | 1979-03-13 | 1980-09-20 | Maruko Seiyaku Kk | Preparation of theobromine derivative |
CS201558B1 (en) | 1979-05-14 | 1980-11-28 | Pavol Kovar | Method of preparing 1-/5-oxohexyl/-3,7-dimethylxanthine |
JPS5677279A (en) | 1979-11-28 | 1981-06-25 | Ota Seiyaku Kk | Preparation of xanthine derivative |
JPS56125451A (en) | 1980-03-08 | 1981-10-01 | Mitsubishi Gas Chem Co Inc | Production of modified asphalt |
JPS5762278A (en) | 1980-10-01 | 1982-04-15 | Sagami Chem Res Center | Theobromine derivative and its preparation |
JPS5780385A (en) | 1980-11-05 | 1982-05-19 | Mitsubishi Petrochem Co Ltd | Preparation of 1-((omega-1)-oxoalkyl)-3,7-dialkylxanthine |
JPS5785387A (en) | 1980-11-14 | 1982-05-28 | Teikoku Chem Ind Corp Ltd | Preparation of 1-(-5'-oxohexyl)-3,7-dimethylxanthine |
JPS5798284A (en) | 1980-12-10 | 1982-06-18 | Kawashima Yakuhin Kaihatsu Kk | Preparation of 1-(5-oxohexyl)-3,7-dimethylxanthine |
JPS5838284B2 (ja) | 1981-04-14 | 1983-08-22 | ミサワホ−ム株式会社 | 脱型装置 |
JPS57200391A (en) | 1981-06-02 | 1982-12-08 | Daito Koeki Kk | 1-(5-oxo-2-hexenyl)3,7-dimethylxanthine |
JPS58134092A (ja) | 1982-02-05 | 1983-08-10 | Sagami Chem Res Center | テオブロミン誘導体 |
JPS58150594A (ja) | 1982-03-03 | 1983-09-07 | Daito Koeki Kk | キサンチン誘導体の製造方法 |
CS237719B1 (cs) | 1983-05-12 | 1985-10-16 | Jan Jendrichovsky | SpAsob přípravy dimetyl-(5-oxohexyl)-xantlnov |
DE3508097A1 (de) | 1984-07-21 | 1986-02-06 | Hoechst Ag, 6230 Frankfurt | Kombinationspraeparat aus xanthinderivaten und o-acetylsalicylsaeure bzw. deren pharmakologisch vertraeglichen salzen und dessen verwendung |
DD274334A3 (de) | 1985-12-17 | 1989-12-20 | Dresden Arzneimittel | Verfahren zur herstellung von reinem 3,7-dimethyl-1-(5-oxohexyl)-xanthin |
IL84934A (en) | 1986-12-31 | 1994-08-26 | Hoechst Roussel Pharma | Pharmaceutical preparations containing xanthan history to stop the activity of interleukin-1 and leukocyte-derived cytokines |
CS263595B1 (en) | 1988-01-06 | 1989-04-14 | Rybar Alfonz | Process for preparing 7-n-propyl-3-methyl-3,7-dihydro-1h-purin-2,6-dione |
JP2661666B2 (ja) | 1988-02-19 | 1997-10-08 | ヘキスト薬品工業株式会社 | 抗消化性潰瘍剤 |
IT1231779B (it) | 1989-08-09 | 1991-12-21 | Eniricerche Spa | Procedimento per l'ossidazione di composti paraffinici. |
US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
DE3942872A1 (de) | 1989-12-23 | 1991-06-27 | Hoechst Ag | Verfahren zur enantioselektiven darstellung von ((omega)-1)-hydroxyalkylxanthinen |
US5112827A (en) * | 1990-05-18 | 1992-05-12 | Board Of Regents, The University Of Texas System | Drug to reverse fatty liver and atheromatous lesions |
WO1992007566A2 (en) | 1990-11-01 | 1992-05-14 | Board Of Regents, The University Of Texas System | Antifungal activity of and prevention of drug induced nephrotoxicity by methylxanthine analogues |
ES2087205T3 (es) | 1990-11-07 | 1996-07-16 | Hoechst Roussel Pharma | Uso de xantinas para la preparacion de un medicamento eficaz para inhibir la replicacion de retrovirus humanos. |
IL100194A0 (en) | 1990-11-30 | 1992-08-18 | Hoechst Roussel Pharma | Use of xanthines for the preparation of a medicament effective for inhibiting the effects of allograft reaction in humans |
IL100195A0 (en) | 1990-11-30 | 1992-08-18 | Hoechst Roussel Pharma | Use of xanthines for the preparation of a medicament having immuno suppressing activity |
US5763446A (en) | 1992-03-26 | 1998-06-09 | University Of Southern California | Use of pentoxifylline and other tumor necrosis factor blockers for the treatment of aids-associated optic neuropathy and other central nervous system diseases |
US5780476A (en) * | 1992-11-16 | 1998-07-14 | Cell Therapeutics, Inc. | Hydroxyl-containing xanthine compounds |
US5716981A (en) | 1993-07-19 | 1998-02-10 | Angiogenesis Technologies, Inc. | Anti-angiogenic compositions and methods of use |
HUT68560A (en) | 1993-08-02 | 1995-04-27 | Chinoin Gyogyszer Es Vegyeszet | The use of xantine derivatives for promotion of healing of operative lesions |
CN1087725C (zh) * | 1994-03-25 | 2002-07-17 | 同位素技术有限公司 | 用氘代方法增强药物效果 |
CA2190511A1 (en) | 1994-05-16 | 1995-11-23 | J. Peter Klein | Asymmetric synthesis of chiral secondary alcohols |
WO1996005836A2 (en) | 1994-08-25 | 1996-02-29 | Medical University Of South Carolina | Methods of treating cold symptoms using pentoxifylline |
DE4430128A1 (de) | 1994-08-25 | 1996-02-29 | Hoechst Ag | Kombinationspräparat mit immunsuppressiven, kardiovaskulären und cerebralen Wirkungen |
US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
DE19544768C1 (de) | 1995-11-30 | 1997-07-10 | Rentschler Arzneimittel | Verwendung einer Kombination aus Pentoxifyllin mit Typ-I-Interferonen zur Behandlung der Multiplen Sklerose |
US6294350B1 (en) | 1997-06-05 | 2001-09-25 | Dalhousie University | Methods for treating fibroproliferative diseases |
US5985592A (en) | 1997-06-05 | 1999-11-16 | Dalhousie University | Uses for pentoxifylline or functional derivatives/metabolites thereof |
US6248889B1 (en) | 1998-11-20 | 2001-06-19 | 3M Innovative Properties Company | Process for converting an alcohol to the corresponding fluoride |
US6417208B1 (en) | 1999-02-05 | 2002-07-09 | Albert Einstein College Of Medicine Of Yeshiva University | Method of identification of inhibitors of PDE1C |
GB9925962D0 (en) | 1999-11-02 | 1999-12-29 | Novartis Ag | Organic compounds |
GB0102107D0 (en) | 2001-01-26 | 2001-03-14 | Syngenta Ltd | Chemical process |
ES2231717T3 (es) | 2001-05-03 | 2005-05-16 | F. Hoffmann-La Roche Ag | Forma de dosificacion farmaceutica del mesilato de melfinavir amorfo. |
CA2446904A1 (en) | 2001-05-24 | 2003-04-03 | Alexza Molecular Delivery Corporation | Delivery of drug esters through an inhalation route |
WO2003013568A1 (en) | 2001-08-02 | 2003-02-20 | Ortho-Mcneil Pharmaceutical, Inc. | Cytokine modulation therapy |
HUP0401998A2 (hu) | 2001-11-02 | 2005-01-28 | Pfizer Products Inc., | PDE9 inhibitorok alkalmazása olyan gyógyszer előállítására, amellyel inzulin-rezisztencia szindróma és 2-es típusú diabétesz kezelhető |
EP1496940A2 (en) | 2002-03-14 | 2005-01-19 | Bayer Pharmaceuticals Corporation | Methods of treating diabetes using pde 11a inhibitors |
DE10214228A1 (de) | 2002-03-22 | 2003-10-02 | Bdd Group Holding Ag Zug | Deuterierte substitutierte Indole sowie diese Verbindungen enthaltende Arzneimittel |
US20050107420A1 (en) * | 2002-05-23 | 2005-05-19 | Boehringe Ingelheim Pharma Gmbh & Co. Kg | Combination of a PDE4 inhibitor and tiotropium or derivative thereof for treating obstructive airways and other inflammatory diseases |
US20040220186A1 (en) | 2003-04-30 | 2004-11-04 | Pfizer Inc. | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease |
AU2004253690B2 (en) | 2003-06-30 | 2010-03-25 | Nycomed Gmbh | Pyrrolodihydroisoquinolines as PDE10 inhibitors |
WO2005012485A2 (en) | 2003-07-31 | 2005-02-10 | Bayer Pharmaceuticals Corporation | Methods for treating diabetes and related disorders using pde10a inhibitors |
WO2005023193A2 (en) | 2003-09-04 | 2005-03-17 | Interleukin Genetics, Inc. | Methods of treating endometriosis |
US20090162286A1 (en) | 2004-06-07 | 2009-06-25 | Pfizer Inc. | Phosphodiesterase 10 Inhibition as Treatment for Obesity-Related and Metabolic Syndrome-Related Conditions |
EP2153824A1 (en) | 2004-09-27 | 2010-02-17 | Sigmoid Pharma Limited | Seamless multiparticulate formulations |
KR20070083839A (ko) | 2004-09-29 | 2007-08-24 | 코디스 코포레이션 | 안정한 무정형 라파마이신 유사 화합물의 약학적 투약 형태 |
BRPI0617987A2 (pt) * | 2005-10-06 | 2011-08-16 | Auspex Pharmaceuticals Inc | composição, composição farmacêutica, forma de dosagem efervescente, composição farmacêutica oral de comprimidos unitários múltiplos, forma de dosagem farmacêutica de liberação prolongada, forma de dosagem farmacêutica revestida entérica, forma de dosagem farmacêutica estável para administração oral a sujeitos mamìferos, método para tratamento de doenças relacionadas a ácido gástrico pela inibição de secreção de ácido gástrico, método para tratamento de uma infecção bacteriana provocada ou mediada por helicobacter pylori, processo para preparar um composto da fórmula 3, processo para preparar um composto da fórmula 5, uso de um composto da fórmula 1 para a preparação de um medicamento para tratamento de doenças relacionadas a ácido gástrico, pela inibição de secreção de ácido gástrico, uso de um composto da fórmula 1 para a preparação de um medicamento para tratamento de uma infecção bacteriana provocada ou mediada por helicobacter pylori uso de um composto da fórmula 1 para a preparação de um medicamento para tratamento de doenças relecionadas a ácido gástrico pela inibição de secreção de ácido gástrico |
CA2716788C (en) * | 2008-02-29 | 2016-08-16 | Concert Pharmaceuticals, Inc. | Deuterium-substituted xanthine derivatives |
-
2010
- 2010-09-01 US US12/873,991 patent/US20110053961A1/en not_active Abandoned
- 2010-09-02 HU HUE10814504A patent/HUE026800T2/en unknown
- 2010-09-02 CN CN201080039090.5A patent/CN102480968B/zh active Active
- 2010-09-02 AU AU2010289465A patent/AU2010289465B2/en active Active
- 2010-09-02 PT PT108145046T patent/PT2473053E/pt unknown
- 2010-09-02 SI SI201030985T patent/SI2473053T1/sl unknown
- 2010-09-02 CN CN201410746544.2A patent/CN104478881A/zh active Pending
- 2010-09-02 PL PL10814504T patent/PL2473053T3/pl unknown
- 2010-09-02 EP EP15163741.0A patent/EP2963040A1/en not_active Withdrawn
- 2010-09-02 KR KR1020127008446A patent/KR101591137B1/ko active IP Right Grant
- 2010-09-02 ES ES10814504.6T patent/ES2542401T3/es active Active
- 2010-09-02 JP JP2012528054A patent/JP5292516B2/ja active Active
- 2010-09-02 DK DK10814504.6T patent/DK2473053T3/en active
- 2010-09-02 MX MX2012002705A patent/MX2012002705A/es active IP Right Grant
- 2010-09-02 IN IN1641DEN2012 patent/IN2012DN01641A/en unknown
- 2010-09-02 EP EP20100814504 patent/EP2473053B1/en active Active
- 2010-09-02 CA CA2771123A patent/CA2771123C/en active Active
- 2010-09-02 ME MEP-2015-108A patent/ME02177B/me unknown
- 2010-09-02 EA EA201270339A patent/EA023809B1/ru not_active IP Right Cessation
- 2010-09-02 BR BR112012008108A patent/BR112012008108B1/pt active IP Right Grant
- 2010-09-02 WO PCT/US2010/047708 patent/WO2011028922A1/en active Application Filing
-
2012
- 2012-02-21 ZA ZA2012/01295A patent/ZA201201295B/en unknown
- 2012-11-05 HK HK12111125.1A patent/HK1170377A1/xx unknown
-
2015
- 2015-07-20 HR HRP20150797TT patent/HRP20150797T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
PL2473053T3 (pl) | 2015-10-30 |
HK1170377A1 (en) | 2013-03-01 |
EP2473053A4 (en) | 2013-03-27 |
CN102480968A (zh) | 2012-05-30 |
EP2473053B1 (en) | 2015-04-22 |
CA2771123C (en) | 2017-11-14 |
HUE026800T2 (en) | 2016-07-28 |
CA2771123A1 (en) | 2011-03-10 |
ME02177B (me) | 2015-10-20 |
CN102480968B (zh) | 2015-01-07 |
BR112012008108B1 (pt) | 2019-10-22 |
ES2542401T3 (es) | 2015-08-05 |
ZA201201295B (en) | 2012-10-31 |
EP2473053A1 (en) | 2012-07-11 |
PT2473053E (pt) | 2015-09-14 |
EA023809B1 (ru) | 2016-07-29 |
KR20120050509A (ko) | 2012-05-18 |
AU2010289465B2 (en) | 2016-03-10 |
SI2473053T1 (sl) | 2015-10-30 |
WO2011028922A1 (en) | 2011-03-10 |
CN104478881A (zh) | 2015-04-01 |
KR101591137B1 (ko) | 2016-02-02 |
EP2963040A1 (en) | 2016-01-06 |
BR112012008108A2 (pt) | 2015-09-22 |
IN2012DN01641A (hr) | 2015-06-05 |
JP2013503894A (ja) | 2013-02-04 |
DK2473053T3 (en) | 2015-07-27 |
US20110053961A1 (en) | 2011-03-03 |
EA201270339A1 (ru) | 2012-09-28 |
MX2012002705A (es) | 2012-04-02 |
JP5292516B2 (ja) | 2013-09-18 |
AU2010289465A1 (en) | 2012-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20150797T1 (hr) | Supstituirani derivati ksantina | |
HRP20192202T1 (hr) | Acc inhibitori i njihove upotrebe | |
HRP20171175T1 (hr) | Novi triciklički spojevi | |
HRP20201243T1 (hr) | N-piperidinil acetamidni derivati kao blokatori kalcijevog kanala | |
HRP20202017T1 (hr) | Sintetski međuprodukt koristan u dobivanju triazolopiridina inhibitora c-met | |
HRP20171512T1 (hr) | Derivati betulina | |
HRP20210529T1 (hr) | Inhibitori za mk2 i njihove uporabe | |
HRP20161577T1 (hr) | Inhibitori replikacije virusa gripe | |
DK3045164T3 (da) | Vandige farmaceutiske sammensætninger, der indeholder borat-polyol-komplekser | |
HRP20221545T1 (hr) | Spiro-lactam nmda receptorski modulatori i njihove uporabe | |
BR112012018345A2 (pt) | "compostos de heteroarila, bem como composições e usos dos mesmos" | |
JP2011518833A5 (hr) | ||
HRP20180196T1 (hr) | Diketoni i hidroksiketoni kao aktivatori puta signalizacije katenina | |
MX349950B (es) | Profarmacos de treprostinil enlazados a un portador. | |
JP2013032389A5 (hr) | ||
JP2014515954A5 (hr) | ||
JP2014516380A5 (hr) | ||
JP2011510079A5 (hr) | ||
JP2013507408A5 (hr) | ||
EA201591957A1 (ru) | Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения | |
JP2012531301A5 (hr) | ||
EA201300990A1 (ru) | Парентеральное введение тапентадола | |
JP2012516348A5 (hr) | ||
JP2009055850A5 (hr) | ||
JP2012501302A5 (hr) |